Pfizer Inc.
Dosing regimen of avelumab for the treatment of cancer
Last updated:
Abstract:
The present invention relates to dosing regimen of avelumab for the treatment of cancer. In particular, the invention relates to improved dosing regimen of avelumab for the treatment of cancer.
Status:
Grant
Type:
Utility
Filling date:
5 Oct 2017
Issue date:
15 Mar 2022